Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 743 matching trials from the live ClinicalTrials.gov search.
Active, not recruiting Not applicable Interventional

tVNS in Long COVID-19

NCT06585254
Conditions
Long COVID, Chronic Fatigue Syndrome
Interventions
Transcutaneous vagus nerve stimulator
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Terminated Phase 3 Interventional Results available

Statins for Acutely Injured Lungs From Sepsis

NCT00979121
Conditions
Sepsis, Acute Lung Injury
Interventions
Rosuvastatin, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
745 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
40
States / cities
Fresno, California • Sacramento, California • San Francisco, California + 20 more
Completed Phase 2 Interventional Results available

Citrulline in Severe Sepsis

NCT01474863
Conditions
Severe Sepsis, Acute Lung Injury
Interventions
High Dose Citrulline, Placebo, Low Dose Citrulline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

NCT04642638
Conditions
Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease
Interventions
INO-4800, CELLECTRA® 2000, Placebo
Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
16
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 12 more
Conditions
Sickle Cell Disease, Anemia, Sickle Cell, Anemia, Hemolytic, Congenital, Respiratory Tract Diseases, Respiration Disorders, Acute Chest Syndrome, Lung Diseases, Asthma, Respiratory Tract Infections, Nutrition Disorders, Deficiency Diseases Vitamin, Vitamin D Deficiency
Interventions
Daily oral vitamin D3, 3,333 IU, Monthly oral vitamin D3, 100,000 IU, Placebo oral tablet
Drug
Lead sponsor
Columbia University
Other
Eligibility
3 Years to 20 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Terminated Phase 3 Interventional Results available

ARrest RESpiraTory Failure From PNEUMONIA

NCT04193878
Conditions
Pneumonia, Hypoxemia, Acute Respiratory Failure, COVID-19 Pneumonia
Interventions
Inhaled budesonide and formoterol, Inhaled placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 8 more
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions
Naltrexone, Ketamine, Placebo
Drug · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Conditions
Influenza
Interventions
Peramivir, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
96
States / cities
Millbrook, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 80 more
Completed Not applicable Interventional Results available

Vagus Nerve Stimulation as Treatment for Long Covid

NCT05608629
Conditions
Long COVID, Chronic Fatigue Syndrome
Interventions
Transcutaneous Non-Invasive Vagus Nerve Stimulation
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Up to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Conditions
Community Acquired Pneumonia (CAP), Sinusitis, Strep Pharyngitis, Acute Otitis Media (AOM)
Interventions
Online Educational Modules, Prescribing Feedback Reports, Clinical Decision Support, Live, hybrid in-person and online educational sessions
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 12 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
SARS-CoV, SARS-CoV-2
Interventions
VXCO-100
Biological
Lead sponsor
Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Decatur, Georgia • Baltimore, Maryland • Rochester, New York
Conditions
Corona Virus Infection, SARS-CoV Infection, Coronavirus
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Post Acute Sequelae Covid-19 Hyposmia
Interventions
Beclomethasone, Placebo, Microsponge
Drug · Other · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Long COVID, Long Covid19
Interventions
Narrative Intervention for Long COVID-19 (NICO)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
AKI, ARDS, COVID
Interventions
SCD
Device
Lead sponsor
SeaStar Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Lexington, Kentucky • Ann Arbor, Michigan • Detroit, Michigan
Terminated Phase 1 Interventional Results available

Camostat With Bicalutamide for COVID-19

NCT04652765
Conditions
Covid19, SARS-CoV Infection, Coronavirus Infection
Interventions
Camostat Mesilate, Bicalutamide 150 mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
60 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
Interventions
Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide, Ceftaroline + Macrolide, Amoxicillin-clavulanate + Macrolide, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir, Amoxicillin-clavulanate + Ceftazidime + Macrolide, Meropenem + Macrolide
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
28 Days and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Conditions
Influenza
Interventions
Nitazoxanide, Oseltamivir, Placebo Oral Tablet, Placebo Oral Capsule
Drug
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
13 Years to 65 Years
Enrollment
1,941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
136
States / cities
Birmingham, Alabama • Dothan, Alabama • Hoover, Alabama + 121 more
Conditions
COVID-19
Interventions
Exercise Prescription
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Frisco, Texas
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Conditions
COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2, Hypoxemia
Interventions
Rejuveinix (RJX) Active Comparator, Placebo Comparator
Drug
Lead sponsor
Reven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Houston, Texas • New Braunfels, Texas
Conditions
Respiratory Syncytial Virus Infections
Interventions
JNJ-53718678, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
28 Days to 3 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Madera, California • Ventura, California • Aurora, Colorado + 11 more
Conditions
RSV Infection
Interventions
Obeldesivir, Obeldesivir Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
121
States / cities
Birmingham, Alabama • Cullman, Alabama • Guntersville, Alabama + 81 more
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis, Severe Acute Respiratory Distress Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Tocilizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Rockville, Maryland • Las Vegas, Nevada • Oklahoma City, Oklahoma + 1 more